180 related articles for article (PubMed ID: 34131633)
1. Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms.
Secardin L; Gomez Limia C; da Silva-Benedito S; Lordier L; El-Khoury M; Marty C; Ianotto JC; Raslova H; Constantinescu SN; Bonamino MH; Vainchenker W; Monte-Mor B; Di Stefano A; Plo I
Hemasphere; 2021 Jul; 5(7):e593. PubMed ID: 34131633
[TBL] [Abstract][Full Text] [Related]
2. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
[TBL] [Abstract][Full Text] [Related]
3. CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes.
Olschok K; Han L; de Toledo MAS; Böhnke J; Graßhoff M; Costa IG; Theocharides A; Maurer A; Schüler HM; Buhl EM; Pannen K; Baumeister J; Kalmer M; Gupta S; Boor P; Gezer D; Brümmendorf TH; Zenke M; Chatain N; Koschmieder S
Stem Cell Reports; 2021 Nov; 16(11):2768-2783. PubMed ID: 34678208
[TBL] [Abstract][Full Text] [Related]
4. Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN.
Benlabiod C; Cacemiro MDC; Nédélec A; Edmond V; Muller D; Rameau P; Touchard L; Gonin P; Constantinescu SN; Raslova H; Villeval JL; Vainchenker W; Plo I; Marty C
Nat Commun; 2020 Sep; 11(1):4886. PubMed ID: 32985500
[TBL] [Abstract][Full Text] [Related]
5. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
[TBL] [Abstract][Full Text] [Related]
6. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
Shide K; Kameda T; Yamaji T; Sekine M; Inada N; Kamiunten A; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Shimoda H; Kitanaka A; Honda A; Sawaguchi A; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Hasuike S; Yamamoto S; Nagata K; Shimoda K
Leukemia; 2017 May; 31(5):1136-1144. PubMed ID: 27807369
[TBL] [Abstract][Full Text] [Related]
7. Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis.
Rivera JF; Baral AJ; Nadat F; Boyd G; Smyth R; Patel H; Burman EL; Alameer G; Boxall SA; Jackson BR; Baxter EJ; Laslo P; Green AR; Kent DG; Mullally A; Chen E
Blood Adv; 2021 Apr; 5(7):1922-1932. PubMed ID: 33821991
[TBL] [Abstract][Full Text] [Related]
8. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
10. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations.
Takei H; Edahiro Y; Mano S; Masubuchi N; Mizukami Y; Imai M; Morishita S; Misawa K; Ochiai T; Tsuneda S; Endo H; Nakamura S; Eto K; Ohsaka A; Araki M; Komatsu N
Br J Haematol; 2018 Jun; 181(6):791-802. PubMed ID: 29741776
[TBL] [Abstract][Full Text] [Related]
11. CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.
Zini R; Guglielmelli P; Pietra D; Rumi E; Rossi C; Rontauroli S; Genovese E; Fanelli T; Calabresi L; Bianchi E; Salati S; Cazzola M; Tagliafico E; Vannucchi AM; Manfredini R;
Blood Cancer J; 2017 Dec; 7(12):638. PubMed ID: 29217833
[TBL] [Abstract][Full Text] [Related]
12. Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.
Salati S; Genovese E; Carretta C; Zini R; Bartalucci N; Prudente Z; Pennucci V; Ruberti S; Rossi C; Rontauroli S; Enzo E; Calabresi L; Balliu M; Mannarelli C; Bianchi E; Guglielmelli P; Tagliafico E; Vannucchi AM; Manfredini R
Sci Rep; 2019 Jul; 9(1):10558. PubMed ID: 31332222
[TBL] [Abstract][Full Text] [Related]
13. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
[TBL] [Abstract][Full Text] [Related]
14. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice.
Shide K; Kameda T; Kamiunten A; Ozono Y; Tahira Y; Yokomizo-Nakano T; Kubota S; Ono M; Ikeda K; Sekine M; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Iwakiri H; Hasuike S; Nagata K; Sashida G; Shimoda K
Blood; 2020 Jul; 136(1):106-118. PubMed ID: 32219445
[TBL] [Abstract][Full Text] [Related]
15. The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.
Olschok K; Altenburg B; de Toledo MAS; Maurer A; Abels A; Beier F; Gezer D; Isfort S; Paeschke K; Brümmendorf TH; Zenke M; Chatain N; Koschmieder S
Front Oncol; 2023; 13():1277453. PubMed ID: 37941547
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
17. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
18. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
Di Buduo CA; Abbonante V; Marty C; Moccia F; Rumi E; Pietra D; Soprano PM; Lim D; Cattaneo D; Iurlo A; Gianelli U; Barosi G; Rosti V; Plo I; Cazzola M; Balduini A
Blood; 2020 Jan; 135(2):133-144. PubMed ID: 31697806
[TBL] [Abstract][Full Text] [Related]
19. Mutant Calreticulin in the Myeloproliferative Neoplasms.
Prins D; González Arias C; Klampfl T; Grinfeld J; Green AR
Hemasphere; 2020 Feb; 4(1):e333. PubMed ID: 32382708
[TBL] [Abstract][Full Text] [Related]
20. Calreticulin in Essential Thrombocythemia: StressINg OUT the Megakaryocyte Nucleus.
Iborra FJ; Papadopoulos P
Front Oncol; 2017; 7():103. PubMed ID: 28589084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
